AIRR - ANZCA Institutional Research Repository
Skip navigation
Please use this identifier to cite or link to this item:
Title: A Retrospective Study of Topical Lidocaine 5% Plasters in Chronic Off-Label Pain Conditions
Authors: Menz, B
Wahba, M
Slattery, P
Thiruvenkatarajan, V
Johnson, J
Keywords: Chronic Pain
Herpes Zoster
Retrospective Studies
Abstract: Dear Editor, Among many formulations, lidocaine (lignocaine) is available in a transdermal plaster (patch) containing 5% w/w lidocaine (Versatis®, trademark of Grünenthal GmbH used by Seqirus as an authorized user). This formulation is approved for symptomatic treatment of neuropathic pain associated with herpes zoster infection (post-herpetic neuralgia); thus, use of these plasters for other pain conditions is considered off-label. The use of lidocaine 5% plasters (L5%P) in off-label indications has been explored in a limited number of small studies. Currently, L5%P are recommended as a second-line treatment for neuropathic pain in a systematic review by Finnerup et al., limited by weak...
Description: Ethics and governance: This project was approved by the Southern Adelaide Local Health Network Human Research Ethics Committee under reference AUD/19/SAC/76 and site-specific assessment reference AR/19/SAC/76
DOI: 10.1093/pm/pnaa408
ORCID: 0000-0002-0855-5081
ISSN: 1526-2375
Journal Title: Pain Medicine
Type: Journal Article
Study/Trial: Study
Appears in Collections:Scholarly and Clinical

Show full item record

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.